Natural occurring molecule rivals Ozempic in weight loss, sidesteps side effects

Meaning of “naturally occurring”

• Commenters debate whether the molecule is really “natural” if it was discovered via in‑silico screening and synthesized in a lab.
• Some argue “naturally occurring” should mean already present in the human body or environment; others note the term is often stretched for marketing, and “natural” ≠ safe or abundant.
• There’s semantic drift: is “natural” anything not human-made, anything found “in nature,” or just “not synthetically invented”? Several see the term as essentially meaningless in consumer health contexts.

Patentability, supplements, and incentives

• One thread claims natural molecules can’t be patented and thus won’t be developed; others point out you can patent derivatives, formulations, delivery methods, or specific medical uses.
• Examples like caffeine, lithium, CBD, aspirin, insulin, and dimethyl fumarate are cited to argue that “natural” has not blocked commercialization.
• Discussion on whether this could have been sold as a supplement: possible, but then it would be lumped in with dubious “weight loss supplements,” and injectable supplements are awkward to market.

How much “AI” was actually used

• The article’s “AI” is criticized as hype. Readers track down the lab’s GitHub and find a Python/R script using pattern recognition (including a big regex) rather than an LLM-style system.
• Several note this is closer to traditional machine learning / motif prediction than what laypeople call “AI,” but “AI” is now used to satisfy investors, journalists, and managers.

Relation to Ozempic / GLP‑1 and markets

• People clarify that GLP‑1 itself is a natural hormone; drugs like semaglutide are longer‑acting receptor agonists inspired partly by Gila monster venom.
• Some expect no immediate impact on Novo Nordisk’s stock: the new molecule is only in animals, human trials will take years, and existing players are already working on next‑gen GLP‑1s. Others note big pharma could simply acquire any serious competitor.

Muscle loss: drug vs. weight loss

• Large subthread on whether GLP‑1 drugs uniquely cause muscle loss or whether this is just what happens with rapid weight loss and calorie restriction.
• Many argue muscle and lean mass loss are primarily driven by deficit size, low protein intake, and lack of resistance training, not GLP‑1 itself.
• Others stress that obese patients can end up sarcopenic after rapid loss, which is a real clinical concern; adequate protein and strength training are strongly recommended.
• Some push back on framing muscle loss as “good” just because a lighter body “needs less muscle,” citing muscle mass as important for longevity and function (including heart health).

Obesity, Ozempic demand, and U.S. context

• Commenters debate why Americans “jump” on these drugs despite gyms and diet information being available.
• Points raised: willpower and adherence are hard; food quality and ultra‑processed diets; stress, poor safety nets, and feeling financially precarious; GLP‑1s lower appetite without requiring lifestyle overhaul.
• Several see the drugs as a practical solution where public-health and behavioral approaches have largely failed.

Safety, side effects, and production challenges

• A long side comment lists Ozempic/semaglutide side effects from Mayo; others note the new molecule is far from proven safer.
• “Natural” is not equated with cheap or easy to make: historical insulin production and venom‑derived drugs are cited as examples where purification, stability, and delivery are hard and expensive.
• Being a small peptide suggests possible recombinant or synthetic production, but formulation (e.g., long‑acting, tolerable dosing) may be nontrivial.

Skepticism about early-stage results

• Multiple commenters emphasize that all data so far are in mice/animals; many promising obesity drugs have failed when moved to humans.
• Some are cautiously optimistic but insist meaningful conclusions must wait for human trials, especially regarding long‑term safety and muscle preservation claims.